{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28.5","upperLimit":"63.4","value":"45.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"The primary objective of the study is to estimate the rate of pathologic complete response (pCR) at the primary site, defined as the absence of any residual invasive cancer on H\\&E evaluation of the resected specimen and all sampled ipsilateral lymph nodes, in patients with newly diagnosed and untreated Stage III-IVA SCCHN of the oral cavity, Oropharynx, Larynx, and Hypopharynx treated with standard neoadjuvant chemotherapy plus Nivolumab, paclitaxel, and carboplatin. Pathologic complete response rate and its associated score 95% confidence interval will be estimated.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive nivolumab IV over at least 30 minutes on day 1, paclitaxel IV on days 1 and 8, and carboplatin IV on days 1 and 8. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.\n\nPaclitaxel: Given IV\n\nCarboplatin: Given IV\n\nNivolumab: Given IV","id":"OG000","title":"Treatment (Nivolumab, Paclitaxel, Carboplatin)"}],"paramType":"NUMBER","populationDescription":"The complete pathologic response rate was 45.45% (15/33) with a 95% Confidence Interval of 28.5% to 63.4%.","reportingStatus":"POSTED","timeFrame":"Up to 26 months","title":"Pathologic Complete Response Rate","type":"PRIMARY","unitOfMeasure":"percentage of complete response"}